8-K filings / November 16, 2026
Lakewood-Amedex Biotherapeutics Inc.: A stock exchange listing notice
Lakewood-Amedex Biotherapeutics Inc. filed a current report (Form 8-K) with the SEC on November 16, 2026. It reports a stock exchange listing notice.
Item 3.01
Stock exchange listing notice
-
Exchange
Nasdaq
From the filing
Source
“On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing. -
What it says
The company does not meet a listing rule
From the filing
Source
“On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing. -
Rule cited
Nasdaq Listing Rule 5550(a)(2)
From the filing
Source
“On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing. -
Notice date
November 10, 2026
From the filing
Source
“On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.